NasdaqGM:NSTG

Stock Analysis Report

Executive Summary

NanoString Technologies, Inc. provides life science tools for translational research and molecular diagnostic products worldwide.

Snowflake

Fundamentals

Adequate balance sheet with concerning outlook.


Similar Companies

Share Price & News

How has NanoString Technologies's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

2.8%

NasdaqGM:NSTG

0.5%

US Life Sciences

0.2%

US Market


1 Year Return

90.0%

NasdaqGM:NSTG

9.0%

US Life Sciences

-0.7%

US Market

NSTG outperformed the Life Sciences industry which returned 11.1% over the past year.

NSTG outperformed the Market in United States of America which returned 0.3% over the past year.


Share holder returns

NSTGIndustryMarket
7 Day2.8%0.5%0.2%
30 Day-14.3%-4.0%-2.7%
90 Day1.5%1.2%1.6%
1 Year90.0%90.0%9.3%9.0%1.6%-0.7%
3 Year67.8%67.8%69.2%67.8%40.0%30.9%
5 Year138.9%138.9%107.8%97.9%53.8%36.8%

Price Volatility Vs. Market

How volatile is NanoString Technologies's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is NanoString Technologies undervalued based on future cash flows and its price relative to the stock market?

11.21x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for NanoString Technologies to establish if it is available at moderate discount.

Unable to calculate intrinsic value for NanoString Technologies to establish if it is available at substantial discount.


Price Based on Earnings

NanoString Technologies is loss making, we can't compare its value to the US Life Sciences industry average.

NanoString Technologies is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for NanoString Technologies, we can't assess if its growth is good value.


Price Based on Value of Assets

NanoString Technologies is overvalued based on assets compared to the US Life Sciences industry average.


Next Steps

Future Growth

How is NanoString Technologies expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

9.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

NanoString Technologies's revenue is expected to grow by 10.9% yearly, however this is not considered high growth (20% yearly).

NanoString Technologies is not considered high growth as it is expected to be loss making for the next 1-3 years.

NanoString Technologies's revenue growth is expected to exceed the United States of America market average.

Unable to compare NanoString Technologies's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.

Unable to compare NanoString Technologies's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if NanoString Technologies will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.


Next Steps

Past Performance

How has NanoString Technologies performed over the past 5 years?

-9.9%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

NanoString Technologies does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare NanoString Technologies's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare NanoString Technologies's 1-year growth to the US Life Sciences industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if NanoString Technologies has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if NanoString Technologies has efficiently used its assets last year compared to the US Life Sciences industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if NanoString Technologies improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is NanoString Technologies's financial position?


Financial Position Analysis

NanoString Technologies is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

NanoString Technologies's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

NanoString Technologies's level of debt (91.2%) compared to net worth is high (greater than 40%).

The level of debt compared to net worth has increased over the past 5 years (31% vs 91.2% today).


Balance Sheet

High level of physical assets or inventory.

Debt is covered by short term assets, assets are 2.4x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

NanoString Technologies has sufficient cash runway for 1.8 years based on current free cash flow.

NanoString Technologies has sufficient cash runway for 1.6 years if free cash flow continues to grow at historical rates of 47.4% each year.


Next Steps

Dividend

What is NanoString Technologies's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate NanoString Technologies's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate NanoString Technologies's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as NanoString Technologies has not reported any payouts.

Unable to verify if NanoString Technologies's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as NanoString Technologies has not reported any payouts.


Future Payout to Shareholders

No need to calculate the sustainability of NanoString Technologies's dividends in 3 years as they are not expected to pay a notable one for United States of America.


Next Steps

Management

What is the CEO of NanoString Technologies's salary, the management and board of directors tenure and is there insider trading?

5.8yrs

Average management tenure


CEO

Brad Gray (42yo)

9.2yrs

Tenure

US$2,527,985

Compensation

Mr. R. Bradley Gray, also known as Brad, has been the Chief Executive Officer and President of NanoString Technologies, Inc. since June 29, 2010. Mr. Gray worked at Genzyme Genetics, the diagnostic service ...


CEO Compensation Analysis

Brad's remuneration is about average for companies of similar size in United States of America.

Brad's compensation has increased whilst company is loss making.


Management Age and Tenure

5.8yrs

Average Tenure

56yo

Average Age

The average tenure for the NanoString Technologies management team is over 5 years, this suggests they are a seasoned and experienced team.


Board Age and Tenure

7.1yrs

Average Tenure

58yo

Average Age

The tenure for the NanoString Technologies board of directors is about average.


Insider Trading

NanoString Technologies individual insiders have only sold shares in the past 3 months.


Recent Insider Transactions

SellUS$204,49307 Jun 19
David Ghesquiere
EntityIndividual
Role
Senior Key Executive
Senior Vice President of Corporate & Business Development
Shares6,954
Max PriceUS$29.41
SellUS$43,240,00022 Mar 19
Clarus Ventures, LLC
EntityCompany
Shares2,000,000
Max PriceUS$21.62

Ownership Breakdown


Management Team

  • Kathy Surace-Smith (60yo)

    VP, General Counsel & Corporate Secretary

    • Tenure: 6.5yrs
  • J. Brown (61yo)

    Senior Vice President of Sales & Marketing

    • Tenure: 2.1yrs
    • Compensation: US$1.08m
  • Tom Bailey (50yo)

    CFO & Treasurer

    • Tenure: 1.6yrs
    • Compensation: US$1.40m
  • Doug Farrell

    Vice President of Investor Relations & Corporate Communications

    • Tenure: 2.9yrs
  • Debbie Krogman

    Vice President of Human Resources

    • Tenure: 5.8yrs
  • Mary Allen (56yo)

    Senior Vice President of Operations & Administration

    • Tenure: 2.3yrs
    • Compensation: US$896.35k
  • Brad Gray (42yo)

    CEO, President & Director

    • Tenure: 9.2yrs
    • Compensation: US$2.53m
  • Philippa Webster

    Senior Principal Scientist

    • Tenure: 0.0yrs
  • Joe Beechem (61yo)

    Senior Vice President of Research & Development

    • Tenure: 7.3yrs
    • Compensation: US$1.07m
  • David Ghesquiere (52yo)

    Senior Vice President of Corporate & Business Development

    • Tenure: 5.8yrs
    • Compensation: US$1.04m

Board Members

  • Bill Young (74yo)

    Independent Chairman

    • Tenure: 9.6yrs
    • Compensation: US$132.86k
  • Elisha Finney (58yo)

    Independent Director

    • Tenure: 2.3yrs
    • Compensation: US$87.86k
  • Chad Waite (63yo)

    Independent Director

    • Tenure: 15.1yrs
    • Compensation: US$97.86k
  • Rob Hershberg (57yo)

    Independent Director

    • Tenure: 4.4yrs
    • Compensation: US$85.36k
  • Kirk Malloy (52yo)

    Independent Director

    • Tenure: 2.9yrs
    • Compensation: US$86.36k
  • Greg Norden (61yo)

    Independent Director

    • Tenure: 7.1yrs
    • Compensation: US$104.36k
  • Brad Gray (42yo)

    CEO, President & Director

    • Tenure: 9.2yrs
    • Compensation: US$2.53m
  • Chad Nusbaum

    Member of Sequencing Advisory Board

    • Tenure: 0.0yrs

Company Information

NanoString Technologies, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: NanoString Technologies, Inc.
  • Ticker: NSTG
  • Exchange: NasdaqGM
  • Founded: 2003
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$966.205m
  • Shares outstanding: 35.44m
  • Website: https://www.nanostring.com

Number of Employees


Location

  • NanoString Technologies, Inc.
  • 530 Fairview Avenue North
  • Seattle
  • Washington
  • 98109
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
NSTGNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDJun 2013
0F1DB (Deutsche Boerse AG)YesCommon StockDEEURJun 2013

Biography

NanoString Technologies, Inc. provides life science tools for translational research and molecular diagnostic products worldwide. The company offers nCounter Analysis System, an automated, multi-applicatio ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/21 01:07
End of Day Share Price2019/08/20 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.